Literature DB >> 12405867

Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.

M Dolores Sánchez Navarro1, Carlos Coloma Milano, Aránzazu Zarzuelo Castañeda, M Luisa Sayalero Marinero, Amparo Sánchez-Navarro.   

Abstract

OBJECTIVE: To evaluate the dosage regimens of ciprofloxacin prescribed for outpatients by applying the principles of antibacterial therapy.
DESIGN: Retrospective analysis of prescription and demographic data.
SETTING: Community pharmacy in Valladolid, Spain. PATIENTS: Fifty male and female patients aged 18-93 years and with bodyweight 41-95kg.
METHODS: Prescribed dosage regimen, age, weight, height, type of infection, comorbidity and coadministered drugs were recorded for each patient. Plasma concentration curves were simulated from literature values of the pharmacokinetic parameters of the drug and the age and weight of the patients. Urine concentrations were estimated from simulated plasma concentrations, literature values of renal clearance and an average urinary flow rate of 2 L/day. The potential efficacy of the prescribed treatment was evaluated from the ratio of the simulated peak plasma concentration (C(max)) to the literature value of the minimum inhibitory concentration (MIC) for the bacterium most probably responsible for the infection (C(max) /MIC). The ratio of area under the plasma concentration-time curve over 24 hours to MIC (AUC24 /MIC) was also estimated for non-urinary infections.
RESULTS: Demographic variables such as age or bodyweight do not seem to be taken in consideration when ciprofloxacin is prescribed, at least in the patients considered here, leading to wide interindividual variability in plasma concentrations. This may not be relevant for urinary infections, since ciprofloxacin concentrates in the urine, leading to high Cmax /MIC ratios in all patients. Simulated plasma concentration-time curves revealed consistent underdosing for systemic infections in young patients over 60kg, for whom the plasma concentrations achieved led to Cmax /MIC and AUC24 /MIC ratios lower than those associated with clinical efficacy and minimal spread of bacterial resistance.
CONCLUSIONS: The standard regimen of ciprofloxacin 250mg every 12 hours prescribed for urinary infections may not be the best choice, since a more convenient regimen of 500mg once daily leads to a higher Cmax /MIC ratio, which is associated with a more significant postantibiotic effect and higher efficacy of fluoroquinolones. For non-urinary infections, the age and weight of patients should be taken into account to achieve optimum plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12405867     DOI: 10.2165/00003088-200241140-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  28 in total

1.  A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.

Authors:  M M Sánchez-Recio; C I Colino; A Sánchez-Navarro
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

2.  Non-hospital consumption of antibiotics in Spain: 1987-1997.

Authors:  A R Bremón; M Ruiz-Tovar; B P Gorricho; P D de Torres; R L Rodríguez
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.

Authors:  A Forrest; S Chodosh; M A Amantea; D A Collins; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

5.  Pharmacokinetics of ciprofloxacin in elderly subjects.

Authors:  M LeBel; G Barbeau; M G Bergeron; D Roy; F Vallée
Journal:  Pharmacotherapy       Date:  1986 Mar-Apr       Impact factor: 4.705

6.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 7.  Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

Authors:  A Sánchez-Navarro; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

8.  Antibiotic availability and use: consequences to man and his environment.

Authors:  S B Levy
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

Review 9.  A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime.

Authors:  A Sánchez-Navarro; C I Colino; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 10.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more
  5 in total

Review 1.  The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.

Authors:  Y-H Chen; W-C Ko; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-04       Impact factor: 3.267

2.  Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.

Authors:  Guillermo Martín-Gutiérrez; Jerónimo Rodríguez-Beltrán; José Manuel Rodríguez-Martínez; Coloma Costas; Javier Aznar; Álvaro Pascual; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Community pharmacy-based research in Spain (1995-2005): A bibliometric study.

Authors:  José Carlos Andrés Iglesias; N Floro Andrés Rodríguez; José Antonio Fornos Pérez
Journal:  Pharm Pract (Granada)       Date:  2007-01

4.  Interaction between Antibiotic Resistance, Resistance Genes, and Treatment Response for Urinary Tract Infections in Primary Care.

Authors:  Hanley J Ho; Mei Xuan Tan; Mark I Chen; Thean Yen Tan; Seok Hwee Koo; Agnes Y L Koong; Lok Pui Ng; Pei Lin Hu; Kee Tung Tan; Peter K S Moey; Eileen Y L Koh; Chia Siong Wong; David C Lye; Ngiap Chuan Tan
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

5.  A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis.

Authors:  J W S Cattrall; E Asín-Prieto; J Freeman; I F Trocóniz; A Kirby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-07       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.